


**Figure 1 Overview of Study Design**




**Part I: Dose-escalation** until MTD and/or RP2D in NHL patients

**Part II: Expansion** with RP2D in about 40 pts with r/r FL and 40 pts with r/r DLBCL

\* In certain cases, patients with PD are allowed to continue treatment acc. to LYRIC criteria

Maximum treatment duration:  $(8 + 9) = 17$  Cycles = 1 year

**Figure 2 Staggered treatment of first and subsequent Patients per Cohort in Cycle 1 and Cycle 2**



\* From 3<sup>rd</sup> patients onwards: no dosing on the same day (at least overnight staggering)